Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial

Keyphrases

• Randomized Placebo-controlled Trial 100%
• Neuromyelitis Optica Spectrum Disorder (NMOSD) 100%
• Inebilizumab 100%
• Placebo 72%
• Rescue Therapy 18%
• Hazard Ratio 9%
• Adverse Events 9%
• Disability 9%
• Serious Adverse Events 9%
• B Cells 9%
• Paralysis 9%
• Efficacy Endpoint 9%
• Risk Reduction 9%
• 18 Years Old 9%
• Evidence-based Treatment 9%
• Expanded Disability Status Scale 9%
• One Dose 9%
• Blindness 9%
• Response System 9%
• Specialty Clinic 9%
• Specialty Hospital 9%
• Safety Endpoints 9%
• Immune-mediated Inflammatory Diseases 9%
• Voice User Interface 9%
• Adjudication Committee 9%
• Clinical Staff 9%
• Anti-CD19 9%
• Interactive Web Response 9%
• Time to Onset 9%
• Permuted Block Randomization 9%
• Data Monitoring Committee 9%

Medicine and Dentistry

• Placebo 100%
• Neuromyelitis Optica 100%
• Inebilizumab 100%
• Adverse Event 18%
• Rescue Therapy 18%
• Hazard Ratio 9%
• B Cell 9%
• Outpatient 9%
• Paralysis 9%
• Inflammatory Disorder 9%
• Intervention Study 9%
• Expanded Disability Status Scale 9%
• Amaurosis 9%